ATRS Antares Pharma Inc.

2.72
+0.01  (+0%)
Previous Close 2.71
Open 2.69
Price To Book 11.33
Market Cap 436647886
Shares 160,532,311
Volume 649,793
Short Ratio
Av. Daily Volume 1,139,339

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved December 8, 2011.
Anturol
Overactive bladder
Approved Oct 14, 2013.
OTREXUP
Rheumatoid arthritis (RA)
Approval announced February 14, 2018.
Makena - auto injector
Reduce the risk of preterm birth in women with a singleton pregnancy
FDA Approval announced October 1, 2018.
XYOSTED (testosterone enanthate)
Testosterone deficiency

Latest News

  1. Antares Pharma to Report First Quarter 2019 Financial and Operating Results
  2. Why Antares Pharma, Inc.'s (NASDAQ:ATRS) CEO Pay Matters To You
  3. New Research: Key Drivers of Growth for Progress Software, Antares Pharma, National Vision, NMI, Waters, and Kelly Services — Factors of Influence, Major Initiatives and Sustained Production
  4. Antares Pharma Announces Receipt of Orphan Drug Designation for the Treatment of Ectopic Pregnancy With Methotrexate
  5. Edited Transcript of ATRS earnings conference call or presentation 28-Feb-19 1:30pm GMT
  6. Antares Pharma Inc (ATRS) Files 10-K for the Fiscal Year Ended on December 31, 2018
  7. AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study
  8. Antares Pharma to Present at the Cowen and Company 39th Annual Healthcare Conference
  9. Antares Pharma Appoints Dr. Karen Smith to Board of Directors and Announces Retirement of Dr. Jacques Gonella
  10. Antares Pharma Inc (ATRS) Q4 2018 Earnings Conference Call Transcript
  11. Antares Pharma Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
  12. Antares Pharma to Present at the Raymond James & Associates 40th Annual Institutional Investors Conference
  13. Antares Pharma to Report Fourth Quarter and Full Year 2018 Financial and Operating Results
  14. Antares Pharma, Inc. (NASDAQ:ATRS): Time For A Financial Health Check
  15. What Kind Of Shareholder Appears On The Antares Pharma, Inc.’s (NASDAQ:ATRS) Shareholder Register?
  16. Antares Pharma Announces the Appointment of Peter S. Greenleaf to Company’s Board of Directors
  17. ATRS: Xyosted & Epi Pen Available for Sale
  18. Should You Buy NanoString Technologies Inc (NSTG)?
  19. Is Noodles & Co (NDLS) A Good Stock To Buy?
  20. Factors of Influence in 2018, Key Indicators and Opportunity within Antares Pharma, Encana, PPG Industries, Cato, Cimarex Energy, and Ormat Technologies — New Research Emphasizes Economic Growth